Quantitative Concept – Page 43

Biden Ramps Up Fight Against High Drug Prices in State of the Union Address

1 year ago talkbio0Tagged Addresses (publication format), Biden administration, Big Pharma, Commercial Drug Sales, drug price, Generic Drug Cost-Sharing Limit, Cell & Gene Therapy, Inflation Reduction Act, Medicare Drug Negotiations, Out-of-Pocket Cap Expansion, Private insurance, Protections, Study models, Union

State of the Union Address, Biden Administration, Big Pharma, Drug Prices, Inflation Reduction Act, Medicare Drug Negotiations, Out-of-Pocket Cap Expansion, Private Insurance Protections, Generic Drug Cost-Sharing Limit, Cell & Gene Therapy Access Model, Commercial Drug Sales Rebates

FDA Greenlights Opdivo Combination Therapy for First-Line Bladder Cancer Treatment

1 year ago talkbio0Tagged cisplatin, Combined, Opdivo, Overall Survival

Overall Survival, Combined, cisplatin, Opdivo

AstraZeneca Commits £650M Expansion for UK Vaccine Hub and Research Campus

1 year ago talkbio0Tagged AstraZeneca, Cambridge/, Economic Growth, England, Environment, Government support, Investments, Life sciences sector, Occupations, operationally, pandemic preparedness, public health protection, Renewable Energy, research, Research and Development, Speke/ Liverpool, Surgical construction, Taxes, UK vaccine

AstraZeneca, £650 million investment, UK vaccine hub, Speke/ Liverpool, Renewable energy, Operationally net-zero facility, Research and Development (R&D) campus, Cambridge/ England, Job creation, Pandemic preparedness, Public health protection, Economic growth, Government support, Tax environment, Life sciences sector

Biden Proposes Expansion of Medicare Drug Price Negotiation Program

1 year ago talkbio0Tagged Bidens, drug price, Health Care, Increased, Mediation, Medicare, scrutiny

Biden, Medicare, Drug Prices, Negotiation, Increased Scrutiny, More Drugs, Health Care Policy

NICE Rejects Coverage for AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Enhertu Due to Cost-Effectiveness Concerns

1 year ago talkbio0Tagged AstraZeneca, Cost Effectiveness, Coverage rejection, Daiichi Sankyo, Enhertu, Health Services, National, Malignant neoplasm of breast, Nitroglycerin/Sodium Citrate/Ethanol Solution, Technology

NICE, Enhertu, AstraZeneca, Daiichi Sankyo, Breast cancer, Cost-effectiveness, Coverage rejection, Technology Appraisal, National Health Service (NHS)

Akero Reinforces Phase III FGF21 Analog Candidate with Enhanced Fibrosis Response Rates in MASH Data Update

1 year ago talkbio0Tagged Analog, Antibody-Drug, Efruxifermin, fibroblast growth factor 21, Fibrosis Response Rate, Improvements, metabolic dysfunction-associated steatohepatitis, Phase IIb HARMONY Study, Statistical Significance

Akero Therapeutics, FGF21 Analog, efruxifermin (EFX), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Phase IIb HARMONY Study, Fibrosis Response Rate, 96 Weeks, Statistically Significant Improvements

J&J Scores First-Line Approval for Rybrevant Combination in Lung Cancer with EGFR Exon 20 Mutations

1 year ago talkbio0Tagged amivantamab-vmjw, Approved, carboplatin-pemetrexed chemotherapy, Disease Progression, EGFR Exon 20, first-line, Insertion Mutation, Johnson and Johnson, Mortality Risk, Non-Small Cell Lung Carcinoma, Objective Response Rate, ORR, Progression-Free Survival, Reduced, Rybrevant, United States Food and Drug Administration

Johnson & Johnson, Rybrevant (amivantamab-vmjw), FDA Approval, First-Line Treatment, Non-Small Cell Lung Cancer (NSCLC), EGFR Exon 20 Insertion Mutations, Carboplatin-Pemetrexed Chemotherapy, Phase 3 PAPILLON Study, Reduced Disease Progression or Mortality Risk, Improved Objective Response Rate (ORR) and Progression-Free Survival (PFS)